

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

TotalSeq(TM)-C0171 anti-human/mouse/rat CD278 (ICOS)

RRID:AB_2800823

Type: Antibody

Proper Citation

BioLegend Cat# 313553, RRID:AB_2800823

Antibody Information

URL: http://antibodyregistry.org/AB_2800823

Proper Citation: BioLegend Cat# 313553, RRID:AB_2800823

Target Antigen: CD278

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: PG

Antibody Name: TotalSeq(TM)-C0171 anti-human/mouse/rat CD278 (ICOS)

Description: This monoclonal targets CD278

Target Organism: rat, mouse, human

Clone ID: Clone C398.4A

Antibody ID: AB_2800823

Vendor: BioLegend

Catalog Number: 313553

Record Creation Time: 20250820T062801+0000

Record Last Update: 20250821T001136+0000

Ratings and Alerts

No rating or validation information has been found for TotalSeq(TM)-C0171 anti-human/mouse/rat CD278 (ICOS).

No alerts have been found for TotalSeq(TM)-C0171 anti-human/mouse/rat CD278 (ICOS).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Spangler A, et al. (2025) Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later. *Immunity*, 58(3), 728.

Sureshchandra S, et al. (2025) Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils. *Immunity*, 58(12), 3130.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. *Cell reports methods*, 3(1), 100388.

Ivanova EN, et al. (2023) mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. *iScience*, 26(12), 108572.

Bachireddy P, et al. (2021) Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. *Cell reports*, 37(6), 109992.